Genetic risk factor of COPD
Even if an individual has never smoked or been unprotected to pollutants for an extended period, they can still develop COPD. Alpha-1 Antitrypsin Deficiency (AATD) is the most commonly known genetic risk factor of COPD in emphysema. Alpha-1 Antitrypsin related COPD is caused by a deficiency of the Alpha-1 in the bloodstream. Without the Alpha-1 Antitrypsin protein, white blood cells begin to harm the lungs and lung deterioration occurs. The World Health Organization and the American Thoracic Society suggests that everyone determined to have COPD be tested for Alpha-1. Pulmonary Conferences also discusses about different types of genes which may be a cause of pulmonary diseases.
- Alpha1-antitrypsin
- Alpha1-antichymotrypsin
- Cystic fibrosis transmembrane regulator
- Vitamin D-binding protein
- Alpha2-macroglobulin
Related Conference of Genetic risk factor of COPD
September 23-24, 2024
15th International Conference on Pulmonary & Respiratory Medicine
Singapore City, Singapore
October 24-25, 2024
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Paris, France
Genetic risk factor of COPD Conference Speakers
Recommended Sessions
- COPD Pathogenesis
- Asthma and COPD
- Chronic Obstructive Pulmonary Disease
- Co-Morbidities of COPD
- COPD and Cardiovascular Diseases
- COPD Complications
- COPD Exacerbations
- COPD Therapeutics
- COPD: Sign and Symptoms
- Epidemiology of COPD
- Genetic risk factor of COPD
- Lung cancer
- Pathophysiology of COPD
- Pulmonary Hypertension
- Types of COPD
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)